Quick Facts

• Non-Small Cell Lung Cancer (NSCLC): Used as adjuvant treatment following surgery and chemotherapy in certain Stage II to IIIA patients with PD-L1 positive tumors. Utilized for first-line treatment in metastatic NSCLC with high PD-L1 expression and no EGFR or ALK aberrations. Also indicated for metastatic NSCLC after disease progression on platinum-containing chemotherapy.
• Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Approved for use in combination with carboplatin and etoposide as a first-line therapeutic option.
• Hepatocellular Carcinoma (HCC): Indicated for use in combination with bevacizumab for adults with unresectable or metastatic HCC who have not received prior systemic therapy.
• Melanoma: Utilized in combination with cobimetinib and vemurafenib for unresectable or metastatic melanoma that is positive for the BRAF V600 mutation.

---

SAFE REWRITE (FULL TEXT)

TECENTRIQ (atezolizumab) is authorized for use in managing specific types of cancer. It is indicated as a therapeutic option for several conditions, often used in combination with other agents or as monotherapy based on disease characteristics and prior treatment history.

In Non-Small Cell Lung Cancer (NSCLC), TECENTRIQ is used as an adjuvant treatment after surgical resection and platinum-based chemotherapy for adult patients with Stage II to IIIA disease whose tumors show PD-L1 expression. It is also indicated for the initial treatment of metastatic NSCLC in individuals with high PD-L1 expression and a tumor without certain EGFR or ALK genomic aberrations. Furthermore, it serves as a treatment option for metastatic NSCLC following disease progression on a platinum-containing chemotherapy regimen.

For patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC), TECENTRIQ is approved for use in combination with carboplatin and etoposide as a first-line approach. It is also indicated, in combination with bevacizumab, for managing Hepatocellular Carcinoma (HCC) that is unresectable or metastatic in individuals who have not received prior systemic treatment.

TECENTRIQ is also used for the treatment of melanoma that is unresectable or metastatic and is positive for the BRAF V600 mutation, when administered in combination with cobimetinib and vemurafenib.

Eligibility Map: Who can and cannot use TECENTRIQ — Official Regulatory Information

Eligibility scope	Official Regulatory Statement
Populations for whom use is allowed	Adult patients are the primary eligible population for all approved indications. Pediatric use is generally not established or not recommended, with an exception for alveolar soft part sarcoma (ASPS) in patients ge 2 years of age.
Populations for whom use is contraindicated	TECENTRIQ is contraindicated for any patient with a known severe hypersensitivity to Atezolizumab or any component of its formulation.
Age-related eligibility rules	Adults are the approved population. Use in older adults (ge 65 years) requires no specific dose adjustment, though data for patients ge 75 years may be more limited.
Condition-specific eligibility rules	Use is restricted in patients with severe renal impairment or moderate-to-severe hepatic impairment because safety and efficacy data have not been studied in these populations.
Pregnancy and lactation eligibility status	Not recommended during pregnancy or breastfeeding. Females of reproductive potential must use effective contraception during treatment and for a minimum of five months following the final dose.
Eligibility-related restrictions	Conditional use applies to patients with a history of allogeneic hematopoietic stem cell transplant (HSCT) or those with active autoimmune disease, requiring close monitoring due to specific risks documented in regulatory labels.

---

Connection to the overall eligibility profile

Official regulatory documents define eligibility by establishing absolute prohibitions based on hypersensitivity, and firm restrictions based on reproductive status. They classify use in pregnant and lactating women as not recommended due to potential risks. Furthermore, use is limited in populations with pre-existing immune conditions or severe organ function impairment due to a lack of established safety data in these groups, restricting use primarily to the adult population.

Interactions with other medicines and products

Atezolizumab (TECENTRIQ) is a humanized monoclonal antibody, and its interaction profile is characterized by pharmacokinetic (PK) neutrality. The drug is cleared primarily by catabolism, a mechanism distinct from the hepatic cytochrome P450 (CYP) enzyme system and common drug transporters. This profile confirms that co-administration with other medicinal products that modulate CYP enzymes is not expected to result in clinically significant changes to Atezolizumab exposure, as documented in official regulatory prescribing information.

Documented Pharmacodynamic Restrictions

The most important documented interactions involve pharmacodynamic (PD) interference. Systemic immunosuppressive medicinal products, including systemic corticosteroids, are subject to mandatory timing restrictions.

Interaction Type	Interacting Agents	Required Restriction
PD Interference	Systemic Immunosuppressants (e.g., corticosteroids)	Must be avoided immediately prior to and concomitantly with the initiation of TECENTRIQ therapy.

This restriction aims to preserve the intended T-cell activity that the drug enhances. Permissible use of systemic corticosteroids is limited to the management of immune-related adverse reactions or at replacement doses (e.g., leq 10 mg/day prednisone equivalent).

Absence of Other Documented Interactions

Official regulatory sources do not document specific interaction-related timing or restrictions concerning food, alcohol, herbal products, or dietary supplements. Furthermore, no specific interaction-based dose adjustments are required for patients with mild-to-moderate renal impairment or mild-to-moderate hepatic impairment, reflecting the consistency of the drug’s interaction profile across these populations.

The mechanism of Atezolizumab (ТЕЦЕНТРИК) is focused on modulating the PD-L1-mediated mechanism of immune suppression used by malignant cells, specifically by targeting a major physiological checkpoint in the immune system.

---

Blocking the PD-L1 Immunosuppressive Signal

Atezolizumab acts as a precise inhibitor by targeting the Programmed Death-Ligand 1 (PD-L1) protein expressed on malignant cells. This molecular blockade prevents the PD-L1 ligand from interacting with its receptors on T-cells, primarily the PD-1 receptor, which effectively halts the delivery of an inhibitory "stand-down" signal. This action modifies the early molecular steps that permit tumor cells to actively suppress the immune response.

---

Reversing T-cell Inhibition and Permitting Lysis

The interruption of the inhibitory PD-L1/PD-1 axis releases the cytotoxic T-lymphocytes (CTLs) from their suppressed state, permitting their proliferation and recognition of tumor antigens. This mechanistic cascade results in the core physiological effect of T-cell activation and the subsequent lysis (destruction) of malignant cells. This action contributes to T-cell-mediated destruction of malignant cells and shifts the local immune signaling dynamics within the tumor microenvironment.

How ТЕЦЕНТРИК is Used

ТЕЦЕНТРИК (Atezolizumab) is administered only by a healthcare professional in a supervised medical setting.

Administration and Dosing Schedule

TECENTRIQ is provided as a concentrate for solution and must be administered exclusively as an Intravenous (IV) infusion after being diluted with 0.9% Sodium Chloride Injection. The adult dosing regimens offer flexibility in scheduling while maintaining comparable exposure, including:

Dosing Regimen	Frequency
840 mg	Every two weeks (Q2W)
1200 mg	Every three weeks (Q3W)
1680 mg	Every four weeks (Q4W)

The choice of schedule depends on the specific approved use and whether the drug is given alone or in combination with other agents.

Infusion Procedure and Duration

The initial infusion of the diluted solution is administered over 60 minutes. If the patient tolerates the first administration, subsequent infusions may be delivered more quickly, typically over 30 minutes. The duration of treatment is generally continued until documented signs of disease progression or the occurrence of unacceptable toxicity.

Special Use Instructions

• Sequence in Combination Therapy: When TECENTRIQ is co-administered with other cancer treatments (like chemotherapy or bevacizumab) on the same day, TECENTRIQ is administered first.
• Specific Populations: No dose adjustment is required for older adults (age 65 years and older) or for patients with mild to moderate renal impairment or mild hepatic impairment.
• Missed Doses: If a scheduled infusion is missed, the dose should be administered as soon as possible, and the original administration schedule must be adjusted to maintain the appropriate interval between doses.

Research evidence / Overview of studies for ТЕЦЕНТРИК

The clinical evaluation of ТЕЦЕНТРИК (atezolizumab) is documented through regulatory sources and peer-reviewed scientific literature, primarily consisting of large randomized controlled trials (RCTs). These studies examine the drug's role in specific types of cancer, either alone or in combination with other treatments. Research provides context, but not individual predictions, and findings describe group patterns, not personal outcomes.

---

Evidence for Non-Small Cell Lung Cancer (NSCLC)

The clinical evaluation of ТЕЦЕНТРИК was conducted across different NSCLC disease stages and prior treatment histories. These studies compare the medicine, often alone or in combination, against either an inactive control (placebo) or a standard therapeutic regimen.

Research Structure for NSCLC in the Adjuvant Setting

Studies were conducted during periods when the patient's cancer had been fully removed by surgery, followed by chemotherapy. The primary research design used was pivotal, randomized, open-label, multi-center trials (RCTs). These trials were applied in populations of adults with Stage II to IIIA NSCLC whose tumors showed expression of the PD-L1 protein. Researchers examined specific outcomes related to how symptoms change over time, including tracking the time patients remained free of disease recurrence or death, which is known as Disease-Free Survival (DFS), alongside overall survival.

Studies reported measurements of DFS that were longer in the group receiving the regimen including the study medicine, compared to the control group in the tested population. The data show patterns related to PD-L1 levels, where the findings appeared less uniform in tumors with lower PD-L1 expression (e.g., 1% to 49%). Currently, long-term effects are not fully established, as the primary regulatory studies continue to monitor the final overall survival (OS) outcome.

Research Structure for Metastatic NSCLC

The medicine was evaluated in two main metastatic settings using randomized, open-label, multi-center trials. In one scenario, research examined its use as an initial therapeutic option for chemotherapy-naïve adults whose tumors had high PD-L1 expression and lacked certain genetic changes (EGFR or ALK aberrations). These trials were applied in research examining outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS). Studies reported OS measurements that were longer in the group receiving the study medicine compared to those receiving chemotherapy alone. Studies also monitored measurements for Objective Response Rate (ORR). The results apply only to the populations studied; thus, there is limited information for patients with low PD-L1 expression or those with specific genetic aberrations.

In a second scenario, ТЕЦЕНТРИК was observed in adult populations whose metastatic NSCLC had progressed after receiving platinum-based chemotherapy. Research compared the medicine against docetaxel. Studies reported that OS measurements were longer in the group receiving the study medicine. However, comparative evidence is lacking, and data are still emerging for the population of patients who have already been treated with a different Immune Checkpoint Inhibitor (ICI).

Evidence for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Evidence for ES-SCLC was built upon pivotal randomized, double-blind, placebo-controlled Phase III trials applied in research contexts involving fluctuating or unstable symptoms. These studies explored the combination of the study medicine with chemotherapy (carboplatin and etoposide) for adults who had not received prior systemic therapy for extensive-stage SCLC.

The studies monitored outcomes related to functional imbalance, specifically Overall Survival (OS) and Progression-Free Survival (PFS). Studies reported measurements of OS and PFS that were longer for the combination regimen group compared to the chemotherapy plus placebo group. Despite these findings, long-term effects are not fully established, as follow-up durations were limited due to the aggressive nature of the condition.

Evidence for Hepatocellular Carcinoma (HCC) and Melanoma

ТЕЦЕНТРИК was studied for both HCC and melanoma in combination with other agents, focusing on specific patient groups.

For Hepatocellular Carcinoma (HCC), randomized, open-label Phase III trials evaluated a combination regimen against the comparator sorafenib for adults with unresectable or metastatic HCC who had not received prior systemic therapy. The research monitored physiological strain or stress, including OS and PFS. Studies reported OS measurements that were longer for the combination regimen compared to the control regimen. However, the study design focused only on the combination, meaning evidence for the study medicine as a single treatment for HCC is limited. The study population excludes patients who received prior systemic treatments, limiting the generalizability of the findings to that group.

For Melanoma, research examined a combination of ТЕЦЕНТРИК with cobimetinib and vemurafenib in randomized, multi-center trials. These trials were restricted to the population of adults with unresectable or metastatic melanoma whose tumors carry the specific BRAF V600 mutation. Studies reported measurements of PFS that were longer for the triplet combination regimen compared to the control regimen. The trials also included measurement of Overall Survival (OS) in the examined population. Results apply only to the populations studied, meaning data for certain groups without this specific mutation remain insufficient.

Long-Term Evidence and Durability of Response

Research exploring short-term symptom changes helps contextualize how patients reported their experience during the defined study periods. However, the evidence derived from settings with varying symptom burdens often focuses on initial survival endpoints, meaning long-term effects are not fully established across all indications. Follow-up durations were limited in some early analyses, and the continued monitoring of patients from key trials is ongoing to provide further insight into the long-term patterns of response.

Evidence in Specific Patient Populations

The research describes that the PD-L1 biomarker was critical in defining the specific population studied for first-line metastatic NSCLC and was also a focus of subgroup analysis in the adjuvant NSCLC setting. In contrast, for ES-SCLC, the primary evidence structure did not require PD-L1 testing to determine the study population. The findings describe group patterns in these selected populations. Evidence is limited for specific demographic groups such as pediatric populations, patients with certain severe pre-existing comorbidities, or individuals who may have been heavily pre-treated with multiple prior lines of therapy.

Research Gaps and Areas of Uncertainty

Research provides context by describing what is known and what remains uncertain. Comparative evidence is lacking for certain scenarios, such as comparing ТЕЦЕНТРИК to other available immune checkpoint inhibitors. The findings were mixed regarding the consistency of observed measurements across certain subgroups (e.g., lower PD-L1 expression in adjuvant NSCLC). Finally, research does not determine whether an individual will respond similarly, and the long-term effects are not fully established due to limited duration in some follow-up studies, requiring continued post-marketing analysis.

Key Studies & References

1. Atezolizumab in Adjuvant NSCLC: Final DFS results from IMpower010
2. Atezolizumab monotherapy vs single-agent chemotherapy in patients with advanced NSCLC ineligible for platinum-doublet chemotherapy (IPSOS trial summary)
3. Atezolizumab plus Bevacizumab for unresectable Hepatocellular Carcinoma (HCC) (IMbrave150 trial data summary)
4. Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma (IMspire150 trial summary)

Common questions about ТЕЦЕНТРИК (FAQ)

Q: Is taking an over-the-counter pain reliever with food required?

Official product labels for over-the-counter pain relievers provide specific Directions for use. While taking the medicine with food is not strictly required for many products, the label may advise this as a way to help prevent potential stomach irritation. Users should consult the specific instructions listed in the Directions or Warnings section of the product label.

---

Q: Is an over-the-counter pain reliever safe for long-term use?

Regulatory product labels contain Warnings that address the duration of use. Official information advises that users should stop use and consult a doctor if pain or fever lasts longer than the specified timeframes, often three days for fever and five days for pain. Regulatory warnings typically address the risk of serious side effects if maximum daily doses are exceeded or if the product is used for longer than the label directs.

---

Q: Can I take an over-the-counter pain reliever for a migraine?

Some over-the-counter pain relievers or specific combination products are labeled with a Use or Indication for the relief of migraine pain. Consumers are directed to check the product's official labeling, as this information will confirm whether the product is specifically approved to treat that condition.

---

Q: Can children 2 years old use it?

The product label's Directions section must be consulted for age-appropriate use. For many products, dosing instructions are not provided for children under a certain age, such as under 2 years old. If a product is not approved for that specific age group, the label typically advises consulting a doctor for appropriate dosing guidance.

---

Q: Does it make you sleepy?

Official product information lists possible side effects in the Warnings section. Certain pain relievers, particularly combination products containing ingredients like an antihistamine or codeine, may specifically list drowsiness as a potential side effect. This possibility depends entirely on the specific product formulation.

How to Store and Dispose of TECENTRIQ

TECENTRIQ (atezolizumab) requires specific storage and handling to maintain its stability, as outlined in official regulatory documents.

Storage Requirements

Condition	Requirement
Unopened Vial	Store refrigerated at 2 C to 8 C (36 F to 46 F).
Light Protection	Keep the vial in the original carton to protect it from light.
Handling	Do not shake the vial. Do not freeze.

Stability After Dilution

Once the product is prepared for infusion, the solution must be administered immediately. If necessary, it may be stored for up to 24 hours under refrigeration (2 C to 8 C) or for up to 6 hours at room temperature (up to 30 C), with this time limit including the full infusion duration.

Disposal

Any unused portion or waste material should be disposed of in accordance with local requirements for cytotoxic or hazardous agents. Spills must be contained and reported according to facility procedures.